Research programme: GPR119 agonists - Rhizen

Drug Profile

Research programme: GPR119 agonists - Rhizen

Latest Information Update: 28 Apr 2016

Price : $50

At a glance

  • Originator Rhizen Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action GPR119 protein agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 12 Jul 2013 Preclinical trials in Type-2 diabetes mellitus in Switzerland (unspecified route)
  • 12 Jul 2013 Research programme: GPR119 agonists - Rhizen is available for licensing as of 12 Jul 2013. http://www.rhizen.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top